The protein encoded by this intronless gene is a bZIPtranscription factor which can bind as a homodimer to certain promoters and enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma. The encoded protein has been shown to bind to the promoter and modulate the expression of the gene encoding leptin, a protein that plays an important role in body weight homeostasis. Also, the encoded protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells.
^Miller, M; Shuman, J. D.; Sebastian, T; Dauter, Z; Johnson, P. F. (2003). "Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha". Journal of Biological Chemistry278 (17): 15178–84. doi:10.1074/jbc.M300417200. PMID12578822.edit
^Szpirer C, Riviere M, Cortese R, Nakamura T, Islam MQ, Levan G, Szpirer J (July 1992). "Chromosomal localization in man and rat of the genes encoding the liver-enriched transcription factors C/EBP, DBP, and HNF1/LFB-1 (CEBP, DBP, and transcription factor 1, TCF1, respectively) and of the hepatocyte growth factor/scatter factor gene (HGF)". Genomics13 (2): 293–300. doi:10.1016/0888-7543(92)90245-N. PMID1535333.
^Cao Z, Umek RM, McKnight SL (October 1991). "Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells". Genes Dev5 (9): 1538–52. doi:10.1101/gad.5.9.1538. PMID1840554.
^ abWang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Timchenko NA (October 2001). "C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4". Mol. Cell8 (4): 817–28. doi:10.1016/S1097-2765(01)00366-5. PMID11684017.
Marcucci G, Mrózek K, Bloomfield CD (2005). "Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.". Curr. Opin. Hematol.12 (1): 68–75. doi:10.1097/01.moh.0000149608.29685.d1. PMID15604894.
Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C (March 2005). "CEBPA point mutations in hematological malignancies". Leukemia19 (3): 329–34. doi:10.1038/sj.leu.2403614. PMID15674366.